Researchers at the University of Pittsburgh have developed fully human monoclonal antibodies (mAbs) targeting the acetylhydrolase PLA2G7, which is secreted by macrophages and interacts with oxidized low-density lipoprotein (oxLDL). These antibodies have shown potential in blocking PLA2G7-mediated inflammation and macrophage activation, offering novel therapeutic avenues for anti-aging and cancer treatment. The antibodies were identified through panning of phage-displayed Fab and VH libraries, and have demonstrated high specificity and efficacy in blocking PLA2G7 enzymatic activity and cell migration.
Antibodies (Basel). 2025 Mar 3;14(1):21. doi: 10.3390/antib14010021